AAM applauds Q1/Q2 House bill passage
Cuts red tape, brings patient faster access to lower-cost medicines.
AAM
AAM and the Biosimilars Council praise FDA announcement on biosimilars clinical efficacy studies and interchangeability
FDA Commissioner Makary joined AAM’s GRx+Biosims 2025 conference today.
AAM requests federal injunction to block Connecticut’s unconstitutional drug price law
Generic pharmaceutical trade group steps in to protect patient access to affordable generic drugs.
AAM pushes back on Colorado drug price cap
AAM President John Murphy III noted that prices for generic and biosimilar medicines keep falling, yet no biosimilar for Enbrel is available in the U.S.
AAM praises Q1/Q2 House bill markup
The bipartisan, bicameral legislation was included in the 2024 year-end spending bill and reintroduced in this Congress.
AAM report: $467B saved by generics and biosimilars in 2024
The Association for Accessible Medicines states that lower-cost drugs saved $3.4 trillion over the past decade but warns that regulatory and pricing pressures threaten the market's long-term viability.
AAM congratulates Dr. Tidmarsh on appointment as CDER director
“We look forward to a collaborative partnership with Dr. Tidmarsh and the larger team at CDER to prioritize regulatory efficiency.”
Medicare drug price negotiation may harm generic and biosimilar development, warns report.
The paper concludes that, although the negotiation program might reduce drug costs initially, it could threaten the long-term sustainability of the generics and biosimilars market, a key driver of lower prescription costs.
Patent thickets and litigation abuses hinder all biosimilars
White paper analyzes problems and solutions to patent abuses.
Groups join the Biosimilars Council and AAM letter of support for interchangeability legislation
39 Groups support the Biosimilar Red Tape Elimination Act.
Mark Ratner joins AAM to lead Government Relations
Ratner will lead AAM’s government relations team across federal and state relations, advocacy, and alliances.
AAM wins legal battle against Minnesota's generic pricing law
A Minnesota law was found by the district court and appeals court to regulate prices in other states unlawfully.
AAM Report: Patent settlements deliver $423 billion in savings
The findings underscore these agreements' vital role in expanding patient access and driving down healthcare costs.
AAM issues comments on Section 232 investigation on pharmaceuticals
“AAM and the generics and biosimilars industry look forward to working with the Commerce Department and the White House to engage constructively on ways to incent more domestic investment in the medicines supply chain,” said John Murphy III, president and CEO.
AAM commends Senate Q1/Q2 bill introduction
Saves more than $800 million over 10 years; brings lower-cost medicines to patients soone
AAM congratulates Dr. Mehmet Oz on confirmation as CMS administrator
“AAM and the Biosimilars Council look forward to working with Dr. Oz and his team at CMS to ensure lower-cost medicines are always available for America’s patients.”